The Role of Molecular Markers in Predicting Response to Therapy in Patients with Colorectal Cancer

2008 ◽  
Vol 12 (2) ◽  
pp. 87-98 ◽  
Author(s):  
Veena Shankaran ◽  
Kari B. Wisinski ◽  
Mary F. Mulcahy ◽  
Al B. Benson
2020 ◽  
Vol 51 ◽  
pp. 84-91 ◽  
Author(s):  
Laura Bracci ◽  
Francesco Lozupone ◽  
Isabella Parolini

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 746 ◽  
Author(s):  
Kodappully S. Siveen ◽  
Afsheen Raza ◽  
Eiman I. Ahmed ◽  
Abdul Q. Khan ◽  
Kirti S. Prabhu ◽  
...  

Colorectal cancer (CRC) is one of the most common cancers worldwide, with high morbidity and mortality rates. A number of factors including modulation of the tumor microenvironment, high metastatic capability, and resistance to treatment have been associated with CRC disease progression. Recent studies have documented that tumor-derived extracellular vesicles (EVs) play a significant role in intercellular communication in CRC via transfer of cargo lipids, proteins, DNA and RNAs to the recipient tumor cells. This transfer influences a number of immune-related pathways leading to activation/differentiation/expression of immune cells and modulation of the tumor microenvironment that plays a significant role in CRC progression, metastasis, and drug resistance. Furthermore, tumor-derived EVs are secreted in large amounts in biological fluids of CRC patients and as such the expression analysis of EV cargoes have been associated with prognosis or response to therapy and may be a source of therapeutic targets. This review aims to provide a comprehensive insight into the role of EVs in the modulation of the tumor microenvironment and its effects on CRC progression, metastasis, and drug resistance. On the other hand, the potential role of CRC derived EVs as a source of biomarkers of response and therapeutic targets will be discussed in detail to understand the dynamic role of EVs in CRC diagnosis, treatment, and management.


Swiss Surgery ◽  
2001 ◽  
Vol 7 (6) ◽  
pp. 243-248
Author(s):  
Scheunemann ◽  
Hosch ◽  
Kutup ◽  
Izbicki

Die Einführung von immunhisto-/zytochemischen und molekularbiologischen bzw. zytogenetischen Methoden in der onkologische Forschung hat trotz vieler nach wie vor bestehender offener Fragen insgesamt zu einem besseren Verständnis der genetischen Ursachen der Tumorentstehung geführt. Darüber hinaus ergaben sich in verschiedenen Studien Hinweise für eine prognostische Relevanz von bestimmten (zyto)genetischen Veränderungen bzw. residualen Tumorzellen in Lymphknoten oder Knochenmark. Bevor diese Untersuchungen jedoch in den klinischen Alltag Einzug halten und therapeutische Konsequenzen abgeleitet werden können, sind weitere prospektive Studien mit groáen Patientenfallzahlen sowie vereinheitlichte und methodologisch praktikable Untersuchungstechniken zu fordern.


2020 ◽  
Vol 04 (03) ◽  
pp. 291-302
Author(s):  
Mariam F. Eskander ◽  
Christopher T. Aquina ◽  
Aslam Ejaz ◽  
Timothy M. Pawlik

AbstractAdvances in the field of surgical oncology have turned metastatic colorectal cancer of the liver from a lethal disease to a chronic disease and have ushered in a new era of multimodal therapy for this challenging illness. A better understanding of tumor behavior and more effective systemic therapy have led to the increased use of neoadjuvant therapy. Surgical resection remains the gold standard for treatment but without the size, distribution, and margin restrictions of the past. Lesions are considered resectable if they can safely be removed with tumor-free margins and a sufficient liver remnant. Minimally invasive liver resections are a safe alternative to open surgery and may offer some advantages. Techniques such as portal vein embolization, association of liver partition with portal vein ligation for staged hepatectomy, and radioembolization can be used to grow the liver remnant and allow for resection. If resection is not possible, nonresectional ablation therapy, including radiofrequency and microwave ablation, can be performed alone or in conjunction with resection. This article presents the most up-to-date literature on resection and ablation, with a discussion of current controversies and future directions.


2020 ◽  
Vol 30 (6) ◽  
pp. 509-518
Author(s):  
Zengtao Bao ◽  
Shanting Gao ◽  
Baoming Zhang ◽  
Wenchao Shi ◽  
Aimin Li ◽  
...  

2018 ◽  
pp. 93-102
Author(s):  
V. A. Solodkiy ◽  
N. V. Nudnov ◽  
V. D. Chhikvadze ◽  
U. S. Stanojevich ◽  
N. I. Sergeev ◽  
...  
Keyword(s):  

2019 ◽  
Vol 24 (39) ◽  
pp. 4605-4610 ◽  
Author(s):  
Atena Soleimani ◽  
Farzad Rahmani ◽  
Gordon A. Ferns ◽  
Mikhail Ryzhikov ◽  
Amir Avan ◽  
...  

Colorectal cancer (CRC) is the leading cause of cancer death worldwide and its incidence is increasing. In most patients with CRC, the PI3K/AKT signaling axis is over-activated. Regulatory oncogenic or tumor suppressor microRNAs (miRNAs) for PI3K/AKT signaling regulate cell proliferation, migration, invasion, angiogenesis, as well as resistance to chemo-/radio-therapy in colorectal cancer tumor tissues. Thus, regulatory miRNAs of PI3K/AKT/mTOR signaling represent novel biomarkers for new patient diagnosis and obtaining clinically invaluable information from post-treatment CRC patients for improving therapeutic strategies. This review summarizes the current knowledge of miRNAs’ regulatory roles of PI3K/AKT signaling in CRC pathogenesis.


Sign in / Sign up

Export Citation Format

Share Document